Research programme: PPAR alpha agonists - MaxoCore Pharmaceuticals

Drug Profile

Research programme: PPAR alpha agonists - MaxoCore Pharmaceuticals

Alternative Names: MC-3001; PPAR alpha agonists research programme - MaxoCore Pharmaceuticals

Latest Information Update: 12 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MaxoCore Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Lipid metabolism disorders

Most Recent Events

  • 12 Jan 2011 This programme is in active development
  • 07 Dec 2010 Research programme: PPAR alpha agonists - MaxoCore Pharmaceuticals is available for licensing as of 07 Dec 2010. http://www.maxocore.com
  • 21 Jul 2004 Preclinical trials in Lipid metabolism disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top